Philip Stitzer
Family Medicine · Moberly, MONPI 1881693323
Payments from drug & device makers
Across 721 payments — averaging $14.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- AbbVie$1K
- Novo Nordisk$1K
- Lilly USA, LLC$1K
- Amgen$848
- Pfizer$489
- plus $4K from 44 others
What the payments were for
- Food & beverage$10,579100%
- Education$150%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,595 in reported general payments places this provider in the 95th percentile of 2,203 family medicine providers in Missouri.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 197 | $127,181 |
| RybelsusSemaglutide | 95 | $102,450 |
| TrulicityDulaglutide | 83 | $84,014 |
| OzempicSemaglutide | 72 | $71,001 |
| FarxigaDapagliflozin Propanediol | 64 | $56,158 |
| XareltoRivaroxaban | 95 | $55,501 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 45 | $46,837 |
| XifaxanRifaximin | 14 | $46,312 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 27 | $36,953 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 29 | $36,558 |
| VraylarCariprazine Hcl | 23 | $33,048 |
| JardianceEmpagliflozin | 31 | $26,857 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 50 | $26,040 |
| LinzessLinaclotide | 34 | $20,538 |
| Breo ElliptaFluticasone/Vilanterol | 43 | $19,235 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskRybelsus, Ozempic | $1,244 | $173,451167 claims |
| PfizerEliquis | $489 | $127,181197 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $1,141 | $97,19896 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arexvy | $184 | $74,100116 claims |
| AbbVieVraylar, Linzess, Restasis | $1,369 | $61,62869 claims |
| AstraZenecaFarxiga, Symbicort | $1,521 | $61,15479 claims |
| Johnson & JohnsonXarelto | $151 | $55,50195 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $228 | $52,89781 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $50 | $42,50144 claims |
| NovartisEntresto | $228 | $19,14023 claims |
| MerckJanuvia | $262 | $12,23317 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,203 family medicine providers in Missouri.
Other family medicine in Moberly
- Timothy JenningsMaryland Heights$30.2M
- William HowittSpringfield$19.9M
- Rupal TrivediSaint Louis$10.6M
- Frederic PraterMaryland Heights$9.1M
- Leea ReedRogersville$7.9M
- Dennis MorrisonSpringfield$5.7M
- Luke van KirkSpringfield$5.6M
- Amy RobertsTown And Country$4M
- Scott KuennenKansas City$2.2M
- George CarrJefferson City$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.